Oncology Researchers Are Beginning to Focus on Ways to Stop Uncontrolled Cancerous Cell Division

According to a recent article in Fierce Biotech, most cancers progress through constant cell division. Scientists at Vanderbilt University are determined to find the reason for this mysterious cell division.…

Continue Reading Oncology Researchers Are Beginning to Focus on Ways to Stop Uncontrolled Cancerous Cell Division
First Patient Dosed in CA-4948 Trial for Hematologic Malignancies
source: pixabay.com

First Patient Dosed in CA-4948 Trial for Hematologic Malignancies

The first patient has been dosed in a Phase 1 clinical trial, which is exploring Curis Inc.'s CA-4948 in conjunction with ibrutinib for hematologic malignancies. Examples of hematologic malignancies include…

Continue Reading First Patient Dosed in CA-4948 Trial for Hematologic Malignancies
Study Shows History of Venous Thromboembolism Causes Increased Risk of Thrombosis Following Cancer Treatment
source: pixabay.com

Study Shows History of Venous Thromboembolism Causes Increased Risk of Thrombosis Following Cancer Treatment

A recent study has found that there is an increased risk of developing recurring thrombosis for cancer patients who have a history of venous thromboembolism, or VTE. The results of…

Continue Reading Study Shows History of Venous Thromboembolism Causes Increased Risk of Thrombosis Following Cancer Treatment

Twist Bioscience Gives Impressive Presentation at the Virtual American Society for Human Genetics 2020 Annual Conference

A recent article in BioSpace highlighted presentations by Twist Bioscience, a rapidly growing genomic and synthetic biology company. Twist presented its product line at the virtual 2020 Annual Meeting of…

Continue Reading Twist Bioscience Gives Impressive Presentation at the Virtual American Society for Human Genetics 2020 Annual Conference
Companion Diagnostics FoundationOne CDx and VITRAKVI Used to Treat Solid Tumors
Source: Pixabay

Companion Diagnostics FoundationOne CDx and VITRAKVI Used to Treat Solid Tumors

In late October, molecular information company Foundation Medicine, Inc. ("Foundation") shared that its diagnostic tool FoundationOne CDx was approved as a companion diagnostic for VITRAKVI (larotrectinib). While FoundationOne CDx will…

Continue Reading Companion Diagnostics FoundationOne CDx and VITRAKVI Used to Treat Solid Tumors